Active clinical trials
Wet / Neovascular AMD
Trial for the Treatment of WET Macular Degeneration
Phase: 3 - B
- Duration: 18 months
- Impact: International
- Treatment: Implantable device for the delivery of Ranibizumab
- Cost to the patient: 0 €
- Travel expenses: Covered
Recruitment closed
Dry / Atrophic AMD
Dry AMD is a chronic, progressive disease that can affect both eyes or asymmetrically. It causes blurred vision or reduced central vision.
Study for the treatment of dry AMD with loss of photoreceptors
- Phase 3
- Duration: 2 years
- Impact: International
- Treatment: Mitochondrial protection agent
- Cost for the patient: €0
- Travel expenses: Covered
Open recruitment
Study for the Treatment of Geographic Atrophy Secondary to Dry AMD
- Phase : 3
- Duration: 2 and a half years
- Impact: International
- Treatment: Human immunoglobulin monoclonal antibody
- Cost to the patient: € 0
- Travel expenses: Covered
Recruitment open
Diabetic macular oedema
This is a condition that occurs in diabetic patients due to the accumulation of fluid in the retina.
Study for the Treatment of Diabetic Macular Oedema (DMO)
- Phase 3
- Duration: 2 years
- Impact: International
- Treatment: Intravitreal
- Cost to the patient: 0 €
- Travel expenses: Covered
Recruitment open
Thyroid Eye Disease (TED)
Thyroid orbitopathy is an immune-mediated disease that affects the function of the thyroid gland and/or the orbital tissues, either together or separately.
Study for the Treatment of Thyroid Eye Disease (TED)
- Duration: 1 year
- Impact: International
- Treatment: Humanised monoclonal antibody
- Cost to the patient: €0
- Travel expenses: Covered
Pending activation
Dry Eye
Study on the treatment of Moderate and Severe Dry Eye related to meibomian gland dysfunction
- Duration: 3 months
- Impact: International
- Treatment: Topical eye formula (drops)
- Cost for the patient: €0
- Travel expenses: Covered
Closed recruitment
Neurotrophic keratopathy
Clinical Trial in Patients with Persistent Corneal Epithelial Defect (PCED)
Treatments for these patients are often limited to lubrication and protection, as there are no approved treatments available for PCED, and in many cases, patients do not respond to standard therapy.
Study for the treatment of moderate to severe PCED due to neurotrophic keratopathy
Phase: 2/3
- Duration: 56 to 84 days
- Impact: International
- Treatment: Ophthalmic gel
- Cost to patient: €0
- Travel expenses: Covered
Open recruitment
Intracorneal Rings
Prospective study to assess the clinical outcome of the Intrastromal Corneal Ring implanted in patients with Keratoconus.
- Duration: 3 years
- Impact: International
- Treatment: Corneal ring implanted using femtosecond laser
- Cost of lenses for the patient: €0
- Travel expenses: Covered
Open recruitment
Intraocular Lenses
Prospective post-market study to evaluate the performance of Phakic Lens in patients with Myopia.
- Duration: 3 years
- Impact: International
- Treatment: Implantation of intraocular phakic lens patients with myopia
- Cost of lenses for the patient: €0
- Travel expenses: Covered
Open recruitment
Post-market clinical follow-up (PMCF) study with a presbyopia-correcting intraocular lens in adults over 55 years of age.
- Duration: 3 years
- Impact: International
- Treatment: Implantation of a presbyopia-correcting intraocular lens for patients with cataracts
- Cost of lenses for the patient: €0
- Travel expenses: Covered
Open recruitment
Study to evaluate the performance of intraocular lenses in patients with cataracts
- Duration: 2 years
- Impact: International
- Treatment: Implantation of a monofocal intraocular lens for patients with cataracts
- Cost of lenses for the patient: €0
- Travel expenses: Covered
Open recruitment
Application form
Please complete the form and select the clinical study that interests you the most. After receiving your application, we will contact you to start the participation process.